94 related articles for article (PubMed ID: 8106091)
1. Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(3):327-30. PubMed ID: 8106091
[TBL] [Abstract][Full Text] [Related]
2. Some behavioral effects of 1,3-di-o-tolylguanidine, opipramol and sertraline, the sigma site ligands.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1996; 48(4):379-95. PubMed ID: 9112678
[TBL] [Abstract][Full Text] [Related]
3. Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-Di-o-tolylguanidine on body temperature in the rat: interactions with BMY 14802 and rimcazole.
Bejanian M; Pechnick RN; Bova MP; George R
J Pharmacol Exp Ther; 1991 Jul; 258(1):88-93. PubMed ID: 1677044
[TBL] [Abstract][Full Text] [Related]
4. Effect of 1,3-di-o-tolylguanidine (DTG), rimcazole and EMD 57445, the sigma receptor ligands, in the forced swimming test.
Skuza G; Rogóz Z
Pol J Pharmacol; 1997; 49(5):329-35. PubMed ID: 9566032
[TBL] [Abstract][Full Text] [Related]
5. [The possible neurochemical mechanisms of the neuroleptic action of buspirone-like serotonin agonists].
Kharin NA; Dolzhenko AT; Titievskiĭ AV; Naletov SV
Eksp Klin Farmakol; 1993; 56(4):12-4. PubMed ID: 8106056
[TBL] [Abstract][Full Text] [Related]
6. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride.
Eltayb A; Wadenberg ML; Schilström B; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 2005 Nov; 372(3):195-202. PubMed ID: 16284783
[TBL] [Abstract][Full Text] [Related]
7. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
Cook L; Tam SW; Rohrbach KW
J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
[TBL] [Abstract][Full Text] [Related]
8. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.
Cusack B; Boules M; Tyler BM; Fauq A; McCormick DJ; Richelson E
Brain Res; 2000 Feb; 856(1-2):48-54. PubMed ID: 10677610
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of neuroleptics with apomorphine-induced behavior in rats as a function of changing levels of dopamine receptor stimulation.
Megens AA; Hendrickx HM; Lavreysen H; Langlois X
J Pharmacol Exp Ther; 2013 Dec; 347(3):681-96. PubMed ID: 24071734
[TBL] [Abstract][Full Text] [Related]
10. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
11. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
Worms P
Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
[No Abstract] [Full Text] [Related]
12. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
[No Abstract] [Full Text] [Related]
13. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
14. Sigma receptor binding affinity and inhibition of apomorphine-induced climbing.
Fritz PM; DeHaven-Hudkins DL; Fleissner LC; Ford-Rice FY; Luttinger D
Eur J Pharmacol; 1993 Apr; 235(2-3):229-35. PubMed ID: 8508904
[TBL] [Abstract][Full Text] [Related]
15. Action of classic and unusual neuroleptics on various behavioral apomorphine-induced effects.
Boissier JR; Puech AJ; Simon P
Adv Biochem Psychopharmacol; 1977; 16():631-4. PubMed ID: 18906
[No Abstract] [Full Text] [Related]
16. Activation of the A10 mesolimbic system by the sigma-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic.
Ceci A; Smith M; French ED
Eur J Pharmacol; 1988 Sep; 154(1):53-7. PubMed ID: 2903063
[TBL] [Abstract][Full Text] [Related]
17. The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.
Kikuchi T; Uwahodo Y; Tottori K; Nakai M; Morita S
Psychopharmacology (Berl); 1997 May; 131(2):108-14. PubMed ID: 9201797
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evidence for the involvement of sigma sites in DTG-induced contralateral circling in rats.
Bastianetto S; Perrault G; Sanger DJ
Neuropharmacology; 1995 Jan; 34(1):107-14. PubMed ID: 7623959
[TBL] [Abstract][Full Text] [Related]
19. Predictability and specificity of behavioral screening tests for neuroleptics.
Worms P; Lloyd KG
Pharmacol Ther B; 1979; 5(1-3):445-50. PubMed ID: 40263
[No Abstract] [Full Text] [Related]
20. NPC 16377, a potent and selective sigma-ligand. II. Behavioral and neuroprotective profile.
Clissold DB; Pontecorvo MJ; Jones BE; Abreu ME; Karbon EW; Erickson RH; Natalie KJ; Borosky S; Hartman T; Mansbach RS
J Pharmacol Exp Ther; 1993 May; 265(2):876-86. PubMed ID: 8098765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
